Current Report Filing (8-k)
October 20 2022 - 8:01AM
Edgar (US Regulatory)
0000316253
false
0000316253
2022-10-15
2022-10-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 20, 2022 (October 15, 2022)
ENZO
BIOCHEM, INC.
(Exact
Name of Registrant as Specified in its Charter)
New
York |
|
001-09974 |
|
13-2866202 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification Number) |
81
Executive Blvd. Suite
3
Farmingdale,
NY |
|
11735 |
(Address of Principal Executive
Office) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (212)
583-0100
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ | | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 par value |
|
ENZ |
|
The New York Stock Exchange |
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
On
October 15, 2022, Enzo Biochem, Inc. (the “Company”) received written notice from David Bench that he was tendering his resignation
as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of the Company, effective November 14, 2022. His
decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies
or practices (financial or otherwise). The Company has accepted Mr. Bench’s resignation, effective as of November 14, 2022.
On
October 19, 2022, the Company’s board of directors appointed Patricia Eckert, CPA as the interim Chief Financial Officer of the
Company, effective following the resignation of David Bench on November 15, 2022.
Prior
to her nearly five years in various finance roles with Enzo, Ms. Eckert served as Accounting Director at Pall Corporation, where she advanced
through multiple accounting and finance roles, ultimately managing a broad team and directly leading all aspects of implementation of
the ASC 606 Revenue Recognition standard, overseeing matters relating to SOX compliance and driving multiple operational and finance cost
savings initiatives. Prior to her tenure at Pall Corporation, Ms. Eckert served as senior Accountant at a midsize accounting firm based
in New York. Ms. Eckert graduated cum laude with a BBA in Accounting and an MBA in Finance, both from Hofstra University in Hempstead,
NY.
Ms.
Eckert has no family relationships with any of the Company’s directors or executive officers, and is not a party to, and does not
have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.
A
copy of the press release announcing the resignation of David Bench and the interim appointment of Ms. Eckert is attached hereto as Exhibit
99.1.
Item 9.01.
Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Enzo Biochem, Inc. |
|
|
|
Date: October 20, 2022 |
By: |
/s/ Hamid
Erfanian |
|
Name: |
Hamid Erfanian |
|
Title: |
Chief Executive Officer |
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024